If you are unable to view this email, click here

For this edition a highlight will be done on the 2nd ACCELENCE’s Scientific and Industrial Committee, held in Bordeaux (Cap Sciences) on September 13th, 2012, on the accreditation of Bordeaux by the National Cancer Institute as a new sites for integrated research on Cancer, and on BERTIN PHARMA, a company located in the Bordeaux areas, involved in preclinical and clinical trials supplies, drug formulation and manufacturing, biosafety and bio-analysis.

One more time, around a hundred public figures of national and international renown from scientific, industrial and political fields contributed to the ACCELENCE’s Scientific and Industrial Committee.

These namely included representatives of industrial companies such as BOEHRINGER INGELHEIM, BRISTOL MEYERS-SQUIBB, DANONE RESEARCH, GRÜNENTHAL, INSTITUT DE RECHERCHE INTERNATIONALE SERVIER, LABORATOIRES NUTRITION ET CARDIOMETABOLISME, LILLY, LUNDBECK SAS, MEDTRONIC, ROCHE, SAINT JUDE MEDICAL, SANOFI and national or international CROs such as AXONAL, EURAXI PHARMA, PREMIER RESEARCH GROUP, QUINTILES; as well as numerous hospital and university researchers in therapeutic areas such as cardiology, dermatology, genetics, metabolic syndromes, neurology, oncology, pediatrics, or rheumatology; and administration officials such as Mr. Jean-Claude GHISLAIN, Director of the Directorate for the Evaluation of Medical Devices (DEDIM) within the Agency National Safety of the Medicine and Health Products (ANSM) and Mr. Olivier LOUVET, Head of PF4 Dept., Directorate for the Provision of Care, Ministry of Health and Social Affairs. The day was opened by the welcoming speeches of Mr. Alain JUPPE, Mayor of Bordeaux and Mr. Alain ROUSSET, President of the Regional Council of Aquitaine and Deputy of Gironde.

This second edition allowed to communicate the first results of ACCELENCE, 16 months after its operational launch, but also to discuss on the evolution of the regulation of medical devices, the Hospital and General Practitioner collaboration, the performance of a trial over several sites of investigation, or the communication towards patients.

Partnerships were also publicized between ACCELENCE, the Bordeaux University Hospital and MEDTRONIC, world leader in implantable medical devices; ACCELENCE and the Charles Perrens Hospital Group; the Côte Basque Hospital Group; The Association for General Practitioners Clinical Research (an association of General Practitioners dedicated to clinical research); ITEC Services; these partnerships aim to the increasing of the Bordeaux region investigation capacity as well as the accessing to a larger number of potential patients.

Participant response

The follow-up questionnaire sent out to all participants received a wide response. Analysis of the replies reveals a high level of satisfaction concerning the organization, content and relevance of this second Committee as well as the support materials provided to the participants. The replies (industry, scientific and institutional fields) are very encouraging; with a majority of respondents (87%) who confirmed that they felt they had contributed to ACCELENCE’s strategy for development or their intention to participate in the next edition (96%).
All elements of this day (videos of the plenary, supports of interventions, program, list of participants) are available on www.accelence.org
The BRIO project (Bordeaux Oncology Integrated Research) led by the Institut Bergonié, partnering teams from the Bordeaux University Hospital, the Bordeaux Segalen University and the Bordeaux University PRES (Center for Research and Higher Studies), is one of the six projects selected by INCa (National Cancer Institute).

INCa has just accredited six new sites for integrated research on Cancer (SIRIC), bringing the total to eight in France. This accreditation enables INCa to consolidate one of the key measures of the 2009-2013 Cancer Plan aiming to strengthen the resources for multidisciplinary research. SIRIC is funded by the Ministry of Health, INCa and INSERM on behalf of Aviesan.

SIRIC programs aim to bring together and organize, in an integrated manner and on the same site, preclinical and clinical research, and research in human and social sciences, epidemiology and public health. They must thus perform, to maximum optimization, research programs combining multidisciplinary components, from preclinical research to the transfer to patients, in the form of diagnostic tests, drugs, social or public health action (prevention and screening).

Six programs are included in BRIO, SIRIC Bordeaux. Four programs focus on specific tumors: breast cancers (NéoBreastnet: neoadjuvant and post-neoadjuvant breast cancer therapy), sarcoma (an integrated program geared towards personalized treatment of sarcomas), myeloid tumors (leukemic hematopoiesis and therapeutic targets) and liver tumors (hepatocellular carcinoma and liver metastasis). Two programs are transversely oriented: Geriatric Oncology (from suboptimal to optimal treatment of cancers in the elderly) and Innovative Molecular Targets and Cancer Treatment. Moreover, we have set up an additional program for the transmission of the results of our research to patients and to the public (How can we improve patient access to information and promote the transfer of research results and interdisciplinary practices?).

Professor Josy Reiffers, Director of the Institut Bergonié:

«... Recognition of this SIRIC is a major step enabling us to effectively formalize all relevant forces towards a common goal, intensify our exchanges between teams from different disciplines and maximize our effectiveness in relation to patients ...»

Professors Pierre Soubeyran (Director of BRIO) and Francois-Xavier Mahon (Deputy Director):

«... Research in oncology conducted by university hospitals should be dedicated to the transfer of results towards patients. To be competitive and innovative, it must be set up with the competent structures, hospitals licensed to treat cancer patients, Universities and Research Units. Moreover, this research must be linked to clinical routine to ensure that the results are effectively transferred to patients. Finally, research must make our strategies converge toward our ultimate goal, improving the care of patients and their prognosis. These principles are the basis of the general strategy of SIRIC Bordeaux, BRIO, and its recognition by the INCa, the INSERM and the DGOS puts us in the best position to carry out our various assignments to the benefit of patients.»

French-style "Comprehensive Cancer Centers", or Centers for comprehensive care.

There are now eight French sites, five in the provinces including Bordeaux and three in the Paris area, with responsibility for major research programs which are exemplary in coherence, discipline integration and competitiveness.

The SIRIC will also be responsible for locally and nationally spreading the knowledge gained from the results of their work. The SIRIC and INCa share objectives of coordination, complementarity and synergy to increase the French position in innovative approaches to personalized medicine for cancer, and the societal dimension of its support.

Just like the "Comprehensive Cancer Centers" of the United States or the British "Cancer Research", the French SIRIC aim to give a strong boost for a high-level of multidisciplinary research and ultimately, to increase the performance of French cancer research in all its aspects: biological, clinical, human and social, epidemiological and relating to public health.

Finally the SIRIC fall within a more comprehensive structure for cancer research, developed by INCa around specific infrastructures (molecular genetics platforms, tumor banks, clinical-biological databases, Centers for early-phase clinical trials...), with which they must be articulated.

For more information: www.bergonie.org

BERTIN Pharma, a company with over 100 people and a turnover of € 12 Millions, stands as one of the leaders on the French CRO market for the Pharmaceutical Industry.

BERTIN Pharma proposes a comprehensive range of services in the drug development process for both human and animal uses in compliance with International Regulatory Affairs (2 GLP facilities - AFSSAPS and AFSSA, 1 GMP facility, for both veterinary and human products), such as:

- Pre-Formulation & Formulation
- Clinical supplies manufacturing and Distribution
- Analytical development
- Regulatory affairs
- Bioanalysis - ADME - Biotransformation
- Pharmacology - Immunogenicity - Microbiological safety
- Development and sales activity for reagents and tools for bioanalysis

BERTIN Pharma markets reagents and tools for bioanalysis in the field of diabetes/obesity, hypertension, inflammation, stress oxidant, etc.

Those tools are based on products dedicated to sample treatment, its dosage, antibodies (monoclonal and polyclonal) and analytical standards.

The brand names distributed are SPI-Bio, Cayman Chemical, @rtMolecule, Biosense, Aterovax, MS2Plex and IBA. 

BERTIN Pharma is also certified as a research center and therefore can make its customers declare their outsourcing part as R&D tax credit.

For more information:
E-Mail: info@bertinpharma.com

Website: www.bertinpharma.com
On September the 30th, 2012, the ACCELENCE team in investigation centers counted 6 co-investigating physicians (cardiology, dermatology & oncology, oncology, pediatrics), 3 CRA (pediatrics, endocrinology, internal medicine & infectious diseases, neurology), 1 laboratory technician and 1 pediatric nurse. These human resources are deployed over 69 clinical trials, aiming to a potential of 460 recruited patients.

Tel : +33 (0)5 56 48 95 10 - Email : contact@accelence.org